Impax Laboratories Inc. (NASDAQ:IPXL)

headyinvestor (61.01) Submitted: 8/16/2011 9:45:27 AM : Start Price: $18.77 IPXL Score: +2.21

IPX-066 showed a 33% vs. 10% reduction in PD symptoms... that is significant my friends.... C/L Dopa market is huge... baby boomers... plus their financials are envious and generics continue to throw cash into the business. Ridiculous margins... small amount of insider buying recently... all and all, a solid play. Ride it up to the approval date for IPX-066, sell half, if it gets approved, buy a couple months after and ride.... also, if Cymbalta generic gets approved, wow.